IP Library Granted Patent US 8,324,232
Granted Patent B2
US 8,324,232 · App. 12/673,413 · Granted Dec 4, 2012

4-pyrimidinesulfamide derivative

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,324,232
App. No.
12/673,413
Granted
Dec 4, 2012
Kind
B2
Abstract

The invention relates to the compound of structural formula (I) and the salts thereof. Said compound is useful as endothelin receptor antagonist. The invention further relates to a process for preparing said compound.

Claims (16)

1. The compound having the formula I

or a salt thereof.

2. A compound of formula I as defined in claim 1 , or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition containing, as active principle, the compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof, and at least one therapeutically inert excipient.

4. A method for the treatment of hypertension comprising administering to a patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt form.

5. A method for the treatment of pulmonary hypertension comprising administering to a patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt form.

6. A method for the treatment of pulmonary arterial hypertension comprising administering to a patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt form.

7. A process for the preparation of the compound of formula I according to claim 1 , which process comprises the following steps:

a) reacting a compound of formula I-2 B

with a compound of formula I-3

wherein G 1 represents a chlorine or bromine atom or a methylsulfonyl or ethylsulfonyl group, in the presence of a strong base; and

b) cleaving the benzyl group of the compound of formula I-1 B obtained in step a)

using, BCl 3 or BBr 3 .

8. The process of claim 7 , which comprises the additional step of reacting a compound of formula I-4

wherein PG represents benzyl and G 2 represents a halogen atom

with ethylene glycol in the presence of a base to obtain the compound of formula I-2 B .

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 042464 FRAME: 0407. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 043017/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2017
From: ACTELION PHARMACEUTICALS LTD
To: IDORSIA PHARMACEUTICALS LTD
Reel/Frame 042464/0407 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2010
From: BOLLI, MARTIN; BOSS, CHRISTOPH; TREIBER, ALEXANDER
To: ACTELION PHARMACEUTICALS LTD.
Reel/Frame 023956/0459 →